- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This document is a semi-annual update to the second edition report. The purpose of this document is to highlight developments that have occurred since July 2013 – namely, in the areas of policy development, implementation and scale-up of the Xpert® MTB/RIF assay and efforts to define the characteristics of next-generation molecular tests that could replace smear microscopy. An updated technology pipeline is included for reference; however, a detailed report on newer technologies, including technologies other than nucleic acid amplification tests (NAATs), will be published in 2014 (third edition).
Keywords: HIV, TB, drug-resistant, diagnostic, testing
This report is part of a broad and ongoing effort by UNITAID to understand the landscape for TB medicines so as to complement other tools and initiatives. As data on TB medicines markets are incomplete, UNITAID intends this report to serve primarily as a platform for stimulating discussion. That is, this report should be considered a preliminary analysis to: 1) engage key stakeholders in discussion of critical market shortcomings related to TB medicines; and 2) to identify potential market-based approaches to remedy these and establish or restore functional market dynamics.
Keywords: TB, treatment, drugs, diagnostics, medicines
The purpose of this report is to highlight new developments and key challenges that UNITAID has faced as an organization and donor during 2012. This report will be the last to follow the Board approved key performance indicators (KPIs) set for the UNITAID Strategy 2010-2012. The report summarizes UNITAID’s results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, ARV, treatment
The purpose of UNITAID is to contribute to the achievement of global long-term goals for HIV, tuberculosis and malaria through its interventions in product markets. These goals have determined the Strategic Objectives described in this Strategy for the coming four years and are shared by the international community at large.
Keywords: HIV/AIDS, TB, malaria, medicines, funding, diagnostics, prevention
The SAARC Member States have more than an estimated 2.0 million TB cases accounting for close to one-third of the total cases of TB in the world. India alone had almost one-fifth of the global disease burden due to TB. India, Pakistan and Bangladesh followed by Afghanistan are the major contributors of disease burden of TB in the SAARC Region. They are countries that have a dubious distinction of being on the list of 22 TB High Disease Countries in the world.
In 2004, the World Health Organization (WHO) published an interim policy on collaborative TB/HIV activities in response to demand from countries for immediate guidance on actions to decrease the dual burden of tuberculosis (TB) and human immunodeficiency virus (HIV). The term interim was used because the evidence was incomplete at that time. Since then, additional evidence has been generated from randomized controlled trials, observational studies, operational research and best practices from programmatic implementation of the collaborative TB/HIV activities recommended by the policy. Furthermore, a number of TB and HIV guidelines and policy recommendations have been developed by WHO’s Stop TB and HIV/AIDS departments. Updated policy guidelines were therefore warranted to consolidate the latest available evidence and WHO recommendations on the management of HIV-related TB for national programme managers, implementers and other stakeholders.
Download this publication
This is the seventeenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and ﬁnancing TB prevention, care and control at global, regional and country levels using data reported by 204 countries and territories that account for over 99% of the world’s TB cases.
Download this publication
The role of ACSM is crucial in achieving a world free of TB and HIV/AIDS. The aim of Advocacy, Communication and Social Mobilization (ACSM) is to support National TB and HIV/AIDS Control Programmes of the SAARC Region to combat stigma and discrimination, improve case detection and treatment adherence, empower people affected by TB and HIV/AIDS and to mobilize political commitment and resources for TB and HIV/AIDS. ACSM strategy incorporates various types of communication programming, including mass media, interpersonal communication, community mobilization and advocacy.
This document highlights the SAARC regional context and points out major TB, HIV/AIDS and TB/HIV co-infection status and concerns, outlines strategy goal, objectives and expected outcomes. This document also explains the Strategy on the basis of its five different components.
Keywords: HIV/AIDS, TB, strategy, co-infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection. The risk of developing TB is between 20 and 37 times greater in people living with HIV than among those who do not have HIV infection. TB is responsible for more than a quarter of deaths in people living with HIV.
Source: WHO. (2010). Guidelines for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource Constrained Settings.
Download this publication